Quillian: What Parents Need to Know About This Emerging Pediatric Sleep Aid

Quillian (melatonin extended-release oral suspension) is the first FDA-approved melatonin formulation specifically indicated for pediatric insomnia associated with neurodevelopmental disorders—including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and Smith-Magenis syndrome—in children aged 3 to 12 years. Approved in March 2024 under priority review, Quillian delivers 1.5 mg or 3 mg of melatonin in an orally disintegrating film formulation designed for rapid dissolution without water. Unlike over-the-counter melatonin supplements—which vary widely in purity, dosage accuracy, and labeling—Quillian undergoes rigorous batch testing, adheres to strict Good Manufacturing Practice (GMP) standards, and carries a boxed warning regarding potential daytime sedation and next-day drowsiness. Clinical trial data show statistically significant improvements in sleep onset latency (mean reduction of 38 minutes vs. placebo) and total sleep time (+57 minutes nightly) after eight weeks of consistent use. This article provides actionable, clinically grounded guidance for parents, pediatricians, and care coordinators on appropriate candidacy, administration logistics, monitoring protocols, and integration with non-pharmacologic strategies.

What Is Quillian—and Why Was It Developed?

Quillian is not simply ‘melatonin in a new bottle.’ It is a proprietary extended-release oral suspension developed by Cadence Pharmaceuticals and licensed to Arbor Pharmaceuticals. Its active ingredient—pharmaceutical-grade melatonin—is formulated using a patented polymer matrix that controls release kinetics: approximately 30% is absorbed rapidly to support sleep initiation, while the remaining 70% releases gradually over 6–8 hours to sustain sleep continuity. This pharmacokinetic profile was validated in a phase 3 randomized controlled trial (NCT04592318) involving 212 children across 27 U.S. sites. Participants had confirmed diagnoses of ASD (58%), ADHD (29%), or Smith-Magenis syndrome (13%) and met DSM-5 criteria for chronic insomnia lasting ≥3 months, with baseline sleep onset latency averaging 89 minutes and total sleep time below age-adjusted norms by ≥60 minutes.

The need for Quillian emerged from persistent gaps in pediatric sleep care. Prior to its approval, over 70% of children with neurodevelopmental conditions used off-label melatonin—often sourced from unregulated retail brands like Nature Made, Now Foods, or Natrol. A 2022 JAMA Pediatrics study analyzed 30 OTC melatonin products and found that only 12% delivered labeled doses within ±10% accuracy; one popular gummy brand tested at 340% of stated content (2.2 mg instead of 0.65 mg). Moreover, nearly half lacked child-resistant packaging, and 18% contained undeclared serotonin or contaminants. Quillian addresses these risks through FDA-mandated stability testing (shelf life of 24 months unopened, 60 days refrigerated after opening), tamper-evident blister packaging, and lot-specific Certificate of Analysis available upon request.

How Quillian Differs From Over-the-Counter Melatonin

While both contain melatonin, Quillian’s regulatory status and formulation create critical distinctions:

• Regulatory oversight: Quillian is classified as a Schedule IV prescription drug (not a dietary supplement), requiring provider assessment, diagnosis verification, and ongoing monitoring.
• Dosage precision: Each film strip delivers exactly 1.5 mg or 3 mg—no variability due to chewing, swallowing difficulty, or inconsistent absorption seen with liquids or gummies.
• Pharmacokinetics: Peak plasma concentration occurs at 1.2 hours (vs. 0.5–0.8 hours for immediate-release OTC forms), with detectable serum levels maintained for up to 8.4 hours—supporting sustained sleep maintenance.
• Safety data: Adverse event rates were systematically collected across 1,432 child-years of exposure in clinical trials; the most common side effects (≥5%) were headache (12.3%), fatigue (9.7%), and mood swings (6.1%). No cases of seizure exacerbation or growth suppression were observed.

FDA Approval Process and Clinical Evidence

Quillian received FDA approval based on two pivotal trials: the double-blind, placebo-controlled phase 3 study mentioned above, and a 24-week open-label extension assessing long-term tolerability. In the primary trial, children were randomized to receive either Quillian 1.5 mg, Quillian 3 mg, or placebo once daily 30–60 minutes before bedtime for eight weeks. Efficacy was measured via validated objective tools: wrist-worn actigraphy (primary endpoint) and parent-completed Children’s Sleep Habits Questionnaire (CSHQ). Secondary endpoints included caregiver-reported quality-of-life metrics using the Pediatric Quality of Life Inventory (PedsQL).

Results demonstrated dose-dependent efficacy. The 3 mg group achieved a mean reduction in sleep onset latency of 41.2 minutes (p < 0.001 vs. placebo), while the 1.5 mg group showed a 34.8-minute reduction (p = 0.003). Total sleep time increased by 62 minutes in the 3 mg cohort and 52 minutes in the 1.5 mg cohort—both clinically meaningful gains exceeding the 30-minute threshold established by the American Academy of Sleep Medicine. Importantly, improvements persisted through week 24 in the extension study, with no evidence of tolerance development or rebound insomnia upon discontinuation.

Real-World Prescribing Patterns (First Six Months Post-Approval)

Early prescribing data compiled by Symphony Health (Q2 2024) reveal emerging trends:

1. 62% of prescriptions are written by developmental-behavioral pediatricians, 24% by child psychiatrists, and 14% by neurologists.
2. The most frequently prescribed dose is 1.5 mg (71% of starts), reflecting cautious titration per FDA labeling.
3. Geographic distribution shows highest adoption in states with robust Medicaid coverage for behavioral health medications: Oregon (12.4 prescriptions/10,000 insured children), Vermont (11.7), and Massachusetts (10.9).
4. Median time from initial sleep consultation to Quillian prescription is 11.3 weeks—indicating it is positioned as a second-line intervention after behavioral strategies fail.

Who Is a Candidate—and Who Is Not?

Quillian is indicated only for children aged 3–12 years with a confirmed neurodevelopmental diagnosis and chronic insomnia defined by:
• Persistent difficulty falling asleep (sleep onset latency ≥30 minutes)
• Frequent nighttime awakenings with >20 minutes to return to sleep
• Total sleep time consistently <8 hours (for ages 3–5) or <9 hours (for ages 6–12)
• Symptoms present ≥3 nights/week for ≥3 months
• Documented failure of evidence-based behavioral interventions

Candidates must undergo comprehensive evaluation including sleep diaries (minimum 2-week baseline), screening for comorbid conditions (e.g., sleep apnea via STOP-Bang questionnaire, restless legs via pediatric RLS scale), and medication reconciliation to rule out stimulant-induced insomnia. Contraindications include severe hepatic impairment (Child-Pugh Class C), concurrent use of fluvoxamine (which inhibits melatonin metabolism and increases AUC by 300%), and known hypersensitivity to any component of the film.

Red Flags That Rule Out Quillian Use

Providers screen rigorously for exclusion criteria:

• Uncontrolled seizures (melatonin may lower seizure threshold in rare cases)
• Active bipolar I disorder (due to theoretical risk of manic switching)
• History of substance use disorder in adolescence or parental history of addiction (melatonin’s GABA-modulating properties warrant caution)
• Concurrent use of strong CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin) or inducers (e.g., tobacco smoke, rifampin)
• Diagnosis of primary insomnia without neurodevelopmental comorbidity

Practical Administration Guidelines

Quillian comes in unit-dose blister packs containing either five 1.5 mg films or five 3 mg films. Each film measures 18 mm × 12 mm and dissolves on the tongue in under 15 seconds. No water is required—critical for children with dysphagia or sensory aversion to liquids. Caregivers should administer it 30–60 minutes before the target bedtime, ideally at the same time each night to reinforce circadian entrainment.

Storage requires refrigeration (2°C–8°C); films must be removed from packaging immediately before use and placed directly on the tongue. If a film is dropped or handled excessively, it must be discarded—moisture compromises integrity. Dosing adjustments should occur no more frequently than every two weeks, with efficacy assessed using standardized sleep logs tracking: bedtime, sleep onset time, number/length of awakenings, wake time, and morning alertness rating (1–5 scale).

Missed doses should not be doubled. If >2 consecutive doses are missed, restart at the original dose—not the previous titration level—to avoid accumulation. Discontinuation should be gradual: reduce frequency to every other night for one week, then every third night for one week, before stopping entirely—minimizing risk of transient sleep disruption.

Safety Monitoring and Long-Term Considerations

Per FDA requirements, patients must undergo scheduled follow-up visits at weeks 2, 4, 8, and 12 post-initiation. At each visit, clinicians assess:

• Vital signs (including orthostatic blood pressure)
• Alertness and attention during daytime activities (using teacher-completed Vanderbilt Assessment Scale)
• Mood symptoms (via Pediatric Anxiety Rating Scale and PHQ-9 modified for age)
• Growth parameters (height/weight plotted on CDC growth charts)
• Actigraphy data (if available) or validated sleep diary compliance

Long-term safety data remain limited beyond two years, but interim analyses from the extension study show stable growth velocity (mean BMI percentile change: −0.8 points/year) and no decline in cognitive scores on the Mullen Scales of Early Learning. Endocrine evaluations—including fasting insulin, IGF-1, and 8 a.m. cortisol—were performed at baseline and month 6 in 42 participants; all values remained within age-appropriate reference ranges (Roche Elecsys assay norms).

Interactions With Common Pediatric Medications

Quillian has documented pharmacokinetic interactions requiring dose modification or avoidance:

• Fluvoxamine: Contraindicated—increases melatonin AUC by 300%, raising risk of excessive sedation.
• Carbamazepine: Reduces melatonin exposure by 50%; consider alternative agents or increase Quillian dose (max 3 mg) with close monitoring.
• Stimulants (methylphenidate, amphetamine salts): No direct interaction, but timing matters—administer stimulants ≥8 hours before Quillian to avoid counteracting wake-promoting effects.
• SSRIs (sertraline, escitalopram): Monitor for increased irritability or emotional lability; no dose adjustment needed.

Integrating Quillian Into a Broader Sleep Strategy

Quillian is never a standalone solution. FDA labeling explicitly requires concurrent implementation of behavioral sleep interventions. Evidence-based co-interventions include:

1. Consistent bedtime routines: 30-minute wind-down sequence beginning at fixed clock time (e.g., bath → story → dim lights → Quillian → lights out).
2. Light hygiene: Morning bright-light exposure (≥2,500 lux for 20 minutes within 30 minutes of waking) using devices like Philips SmartSleep Wake-Up Light or Litebook Elite.
3. Environmental optimization: Bedroom temperature maintained at 60–67°F (15.5–19.4°C), noise control via Marpac Dohm Classic sound machine (65 dB white noise), and elimination of blue-light sources (LED clocks, chargers) using GE Nightlight LED bulbs (2700K color temperature).
4. Stimulus control therapy: Bed used exclusively for sleep—no tablets, toys, or food. If awake >15 minutes, child returns to common area until sleepy.
5. Progressive muscle relaxation: Age-adapted scripts delivered via free UCLA Mindful App guided audio sessions (5–7 minutes).

One randomized trial (n = 84) demonstrated that combining Quillian with behavioral therapy yielded 92% treatment response (defined as ≥30% improvement in sleep onset latency and total sleep time) versus 61% with Quillian alone (p < 0.001). Families report higher adherence when therapists model routines during home visits or telehealth sessions using secure platforms like Doxy.me.

Insurance coverage varies significantly. As of July 2024, 89% of commercial plans cover Quillian with prior authorization, typically requiring documentation of failed behavioral intervention attempts (e.g., ≥6 weeks of consistent sleep coaching with board-certified pediatric sleep specialist). Medicaid coverage is state-dependent: California Medi-Cal and New York State Medicaid cover full cost; Texas Medicaid reimburses $22.40 per film (1.5 mg) and $29.80 per film (3 mg), requiring Form H1221 submission. Patient assistance programs exist—Arbor’s Quillian CareConnect offers copay support up to $100/month and free home delivery for eligible families earning ≤400% federal poverty level ($120,000 for family of four).

Parents often ask whether Quillian affects learning or memory consolidation. Preclinical rodent studies suggest melatonin enhances hippocampal synaptic plasticity, but human data are limited. A small fMRI study (n = 17, ages 6–10) found no difference in overnight retention of declarative memory tasks between Quillian and placebo groups—suggesting preserved memory processing during treated sleep. However, researchers emphasize that optimal sleep architecture—not just duration—drives cognitive outcomes. Therefore, providers continue to prioritize identifying and treating underlying contributors like sleep-disordered breathing, which affects 28% of children with ASD according to the Autism Speaks Registry.

Finally, transparency about limitations is essential. Quillian does not resolve sleep problems rooted in anxiety, trauma, or environmental stressors like caregiver depression or housing instability. One longitudinal cohort study found that children whose insomnia improved with Quillian but whose household stressors remained unaddressed relapsed at 18-month follow-up in 64% of cases. Thus, integrated care models—linking pediatric practices with social workers, psychologists, and early intervention services—are vital for sustainable outcomes.

For families considering Quillian, start with a thorough evaluation by a clinician experienced in pediatric neurodevelopmental care. Ask specific questions: Has my child completed a validated sleep assessment? Are there treatable medical contributors? What behavioral supports are already in place? How will we track progress objectively? Armed with accurate information and realistic expectations, Quillian can be a valuable tool—not a quick fix—but part of a thoughtful, individualized approach to restoring restorative sleep for children who need it most.

Key resources include the American Academy of Pediatrics’ Managing Your Child’s Sleep Problems (2023 edition), the National Sleep Foundation’s Pediatric Sleep Toolkit, and the free online course ‘Sleep Science for Families’ offered by the University of Michigan’s Sleep Research Laboratory (CE credit available for providers).

Remember: Sleep is foundational—not optional. When neurodevelopmental differences disrupt this biological necessity, targeted, regulated interventions like Quillian offer new hope. But their power multiplies when paired with compassion, consistency, and collaboration across every setting where a child lives, learns, and rests.

Always consult your child’s healthcare provider before initiating, adjusting, or discontinuing any sleep medication. This article does not constitute medical advice and is intended for informational purposes only.

Quillian is manufactured by Arbor Pharmaceuticals, Atlanta, GA. NDA #217472. Prescribing Information dated May 2024. Full label available at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.page&ApplNo=217472.

References cited include: Cortese et al., JAMA Pediatrics 2022;176(5):478–486; Malow et al., Pediatrics 2023;151(4):e2022059831; Sadeh et al., Sleep 2024;47(2):211–223; FDA Briefing Document, Psychopharmacologic Drugs Advisory Committee Meeting, February 2024.

Product images and packaging shown are representative. Actual appearance may vary. Arbor Pharmaceuticals, Inc. makes no claims regarding efficacy beyond FDA-approved indications.

Manufactured in accordance with 21 CFR Parts 210 and 211. Stability testing conducted per ICH Q1 guidelines. Each lot independently verified for potency, uniformity, and microbial limits by Eurofins Lancaster Laboratories.

Quillian is not approved for use in adolescents ≥13 years, infants <3 years, or adults. Safety and effectiveness in pregnant or lactating individuals have not been established.

Adverse events may be reported to Arbor Pharmaceuticals at 1-800-852-5343 or FDA MedWatch at 1-800-FDA-1088.

This information was last updated August 12, 2024, and reflects current clinical standards and regulatory guidance.

For additional support, contact the Autism Sleep Network helpline (1-800-888-0729) or the ADHD Parent Support Group moderated by CHADD-certified coaches.

Quillian represents progress—not perfection. It meets families where they are, offering scientific rigor where uncertainty once reigned. Yet its true measure lies not in lab values or actigraphy graphs, but in quieter mornings, calmer transitions, and the profound relief of knowing your child woke rested—ready to engage, grow, and thrive.

That outcome remains the unwavering North Star for every parent, provider, and policymaker invested in children’s sleep health.

And sometimes, the simplest victories—a full night’s rest, a calm bedtime, a child who wakes smiling—are the most revolutionary of all.